Feb 22 |
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
|
Feb 15 |
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for
|
Feb 15 |
Alnylam changes to heart drug trial spark doubts, sinking shares
|
Feb 7 |
BridgeBio grants Japanese rights to Kyowa Kirin for dwarfism drug
|
Feb 7 |
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
|
Feb 7 |
BridgeBio sells partial rights to dwarfism drug for $100M
|
Feb 5 |
BridgeBio Pharma granted FDA review for amyloidosis therapy
|
Feb 5 |
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
|
Feb 2 |
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
|
Jan 30 |
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
|